Neuronetics Links NeuroStar TMS With AdvancedMD Platform

BTIG maintained a Buy rating on Neuronetics with a $6 price target, suggesting 117.4% upside from the last close. The company reported 17% revenue growth and introduced a new go-to-market strategy, aiming to expand its customer base and improve operational efficiency.

Neuronetics Inc (STIM) shares rose 3.5% after B.Riley initiated coverage with a Buy rating and $5.00 price target, citing potential earnings growth from the Greenbrook acquisition and a shift in interventional psychiatry. The analyst sees 70% upside from current levels, noting STIM trades at a lower multiple than peers.

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

Neuronetics (STIM) reported Q2 2026 revenue of $41.6 million, up 9.1% year over year, with Greenbrook revenue rising 16.8% to $26.9 million. Gross margin increased to 51.1%. Adjusted EBITDA turned positive at $0.3 million. Net loss narrowed to $3.4 million. Full-year 2026 revenue guidance is $160-$164 million and gross margin 48%-50%.